25 May 2013
Keywords: doxorubicin, transdrug, performs, well, liver, cancer, study
Article | 10 July 2006
French specialty pharmaceutical company BioAlliance Pharma says that it has achieved promising results from a Phase I/II study of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 July 2006
17 July 2006
24 May 2013
© 2013 thepharmaletter.com